Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855175 | 1.00 | AHCY (0.47) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL2520562 | 0.90 | AHCY (0.47) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL25659855 | 0.90 | AHCY (0.45) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL25867818 | 0.88 | PNP (0.39) | LMNAADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2524440 | 0.88 | PDE4D (0.53) | LMNANT5EADORA3ADORA2AADORA1 | |
| SCHEMBL21709764 | 0.88 | AHCY (0.34) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL12214180 | 0.85 | AHCY (0.41) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL13581562 | 0.85 | AHCY (0.42) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL29790376 | 0.84 | AHCY (0.41) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL21709653 | 0.83 | AHCY (0.40) | AHCYLMNANT5EHIF1ACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7339053-B2 | 4′-C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2008-03-04 | — | — | US | claimed |
| EP-1589026-A1 | 4'-C-Substituted-2-Haloadenosine derivative | YAMASA CORPORATION (JP) | 2005-10-26 | — | — | EP | claimed |
| US-20050215512-A1 | 4' -C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2005-09-29 | — | — | US | claimed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3413897-B1 | METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS | MERCK SHARP & DOHME LLC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220010316-A1 | ENGINEERED PURINE NUCLEOSIDE PHOSPHORYLASE VARIANT ENZYMES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-01-13 | — | — | US | disclosed |
| US-11162105-B2 | Engineered purine nucleoside phosphorylase variant enzymes | CODEXIS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021038509-A1 | 4'-ETHYNYL-2'-DEOXYADENOSINE DERIVATIVES AND THEIR USE IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021024114-A1 | 4'-ETHYNYL-2'-DEOXYADENOSINE DERIVATIVES AND THEIR USE IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-11 | — | — | WO | disclosed |
| US-20090234110-A1 | 4' -C-substituted-2-haloadenosine derivative | KOHGO SATORU | 2009-09-17 | — | — | US | disclosed |
| US-20080153774-A1 | Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase | KOHGO SATORU | 2008-06-26 | — | — | US | disclosed |
| US-20080153774-A1 | Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase | KOHGO SATORU | 2008-06-26 | — | — | US | disclosed |
| US-20080153774-A1 | Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase | KOHGO SATORU | 2008-06-26 | — | — | US | disclosed |
| US-7339053-B2 | 4′-C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2008-03-04 | — | — | US | disclosed |
| US-7339053-B2 | 4′-C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2008-03-04 | — | — | US | disclosed |
| US-7339053-B2 | 4′-C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2008-03-04 | — | — | US | disclosed |
| EP-1589026-A1 | 4'-C-Substituted-2-Haloadenosine derivative | YAMASA CORPORATION (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20050215512-A1 | 4' -C-substituted-2-haloadenosine derivative | YAMASA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | AHCY 1161/4885LMNA 2608/4885NT5E 1408/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | AHCY 248/4885LMNA 3687/4885NT5E 159/4885 |
| US-20080153774-A1 | Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase | ADA, PNP, DCTD | AHCY 69/4885LMNA 4513/4885NT5E 49/4885 |
| US-20050215512-A1 | 4' -C-substituted-2-haloadenosine derivative | ADORA1, ADORA2A, ADORA3 | AHCY 259/4885LMNA 3258/4885NT5E 170/4885 |
| US-20090234110-A1 | 4' -C-substituted-2-haloadenosine derivative | ADORA1, ADORA2A, ADORA3 | AHCY 59/4885LMNA 3655/4885NT5E 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.